Cordova-Delgado Miguel, Pizarro Gonzalo, Pinto Mauricio P, Herrera Maria Elisa, Garrido Marcelo
Hematology and Oncology Department, Faculty of Medicine, Pontificia Universidad Católica de Chile (PUC), Santiago, Chile.
Faculty of Chemical and Pharmaceutical Sciences, Universidad de Chile, Santiago, Chile.
Front Oncol. 2021 Mar 10;11:593561. doi: 10.3389/fonc.2021.593561. eCollection 2021.
Small bowel adenocarcinoma (SBA) is a rare malignancy characterized by poor prognosis. Recent efforts have sought to elucidate the genetic landscape and the molecular drivers behind this disease. Herein, we report the main molecular alterations in two metastatic (stage IV) SBA patients. Interestingly, one of them had gene alterations that affected signaling pathways previously described for SBA. However, a second patient displayed previously unreported alterations in this particular tumor type. Based on these findings we discuss potential treatment options for patients affected by this rare, aggressive disease.
小肠腺癌(SBA)是一种预后较差的罕见恶性肿瘤。最近的研究致力于阐明这种疾病背后的基因图谱和分子驱动因素。在此,我们报告了两名转移性(IV期)SBA患者的主要分子改变。有趣的是,其中一名患者的基因改变影响了先前报道的SBA信号通路。然而,另一名患者在这种特定肿瘤类型中表现出先前未报道的改变。基于这些发现,我们讨论了受这种罕见侵袭性疾病影响的患者的潜在治疗选择。